ATRC — AtriCure, Inc.

AtriCure Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $141.2 million for Q1 2026, up 14.3% year-over-year (12.8% on a constant currency basis).
• U.S. Revenue: $116.2 million, a 14.9% increase from Q1 2025.
• Adjusted EBITDA: $17.1 million, nearly double the $8.8 million reported in Q1 2025.
• Net Income: Approximately breakeven at $100,000, compared to a net loss of $6.7 million in Q1 2025.
• Gross Margin: 77.4%, an increase of 246 basis points year-over-year.
• Cash Position: Ended the quarter with $146 million in cash and investments.

2. Strategic Updates and Business Highlights

• Product Performance:
  • Pain management segment grew 28% year-over-year, driven by the cryoSPHERE MAX probe.
  • Open ablation revenue increased 15%, supported by the EnCompass clamp.
  • Appendage management products saw a 16% growth, with AtriClip FLEX-Mini contributing significantly.
• Clinical Trials: Rapid enrollment in the BoxX-NoAF trial, with 300 patients enrolled, expected to complete enrollment by year-end 2026, nearly a year ahead of schedule.
• International Expansion: Received CE Mark for AtriClip FLEX-Mini and PRO-Mini, with plans to launch in Europe later this year.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Reiterated full-year revenue expectations of $600 million to $610 million, reflecting 12% to 14% growth over 2025.
• Adjusted EBITDA Guidance: Expected to be between $80 million and $82 million for the full year.
• Q2 Expectations: Anticipate mid-single-digit sequential growth, with continued strong performance in pain management and open ablation franchises.

4. Bad News, Challenges, or Points of Concern

• International Headwinds: Continued uncertainty in the U.K. market and lower distributor sales in Asia, with no immediate recovery anticipated.
• Minimally Invasive Ablation Segment: Experienced a 25% decline in U.S. sales, indicating ongoing challenges in this area.
• Increased Operating Expenses: Total operating expenses rose by 10.3%, driven by rapid clinical trial enrollment and increased headcount for product development.

5. Notable Q&A Insights

• PFA Integration: Progressing well with first-in-human trials in Australia and Europe, with an expected FDA submission later this year.
• Pain Management Growth: 70% of pain management accounts have adopted cryoSPHERE MAX, with a 10% growth in accounts during the quarter.
• BoxX-NoAF Trial Feedback: Anecdotal positive outcomes from clinicians using the EnCompass clamp and AtriClip, contributing to accelerated enrollment.
• Competitive Landscape: AtriCure maintains a strong market position despite competition, particularly in appendage management, with ongoing innovation and clinical evidence supporting their products.

Overall, AtriCure's Q1 2026 results reflect strong growth and strategic advancements, though challenges in international markets and specific product segments remain areas of concern. The company is optimistic about future growth driven by ongoing clinical trials and product launches.